Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Individualised cryoneurolysis for pain from spasticity in the arms and legs

Official title: Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities (ICE): a Pilot Randomised Controlled Trial

Run by Oxford University Hospitals NHS Trust · NCT07303582 · Data updated 2026-11-12

This will try freezing specific nerves (cryoneurolysis) or using botulinum toxin to see which reduces pain from spasticity in adults with stroke, spinal cord injury, brain injury, or multiple sclerosis.

More Multiple Sclerosis trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorOxford University Hospitals NHS Trust
Academic / other
Locations1 site (Oxford)
StatusRecruiting
StartedDecember 2, 2025
Main results expectedNovember 1, 2027
Study endsApril 1, 2028
Registry record updatedNovember 5, 2026
Trial IDNCT07303582 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) with a central neurological condition (acquired brain injury including stroke, multiple sclerosis, or spinal cord injury), pain related to spasticity, a clinical indication for botulinum toxin or cryoneurolysis, and a positive diagnostic nerve block to targetable nerves.

Probably not a fit

People with recent botulinum toxin or cryoneurolysis within 90 days, or with contraindications such as Raynaud's syndrome, cryoglobulinaemia, or cold urticaria, and those whose spasticity does not respond to diagnostic nerve block are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot, randomized comparison at Oxford will allocate eligible adults with central nervous system conditions and pain from spasticity to receive either targeted cryoneurolysis or standard botulinum toxin injections. Cryoneurolysis uses controlled freezing of nerve tissue to temporarily disrupt nerve function and relieve pain, while botulinum toxin reduces muscle overactivity through chemical denervation. Participants must show a meaningful response to a diagnostic nerve block for treatable nerves before enrollment and will be followed for effectiveness and side effects. The goal is to gather preliminary data on pain relief, functional impact, duration of benefit, and adverse events to inform larger trials and clinical use.

Why it matters

Potential benefit: If successful, cryoneurolysis could provide longer-lasting pain relief from spasticity with fewer repeat treatments and lower overall treatment burden than repeated botulinum toxin injections.

How similar studies have gone: Cryoneurolysis has been approved in the UK for pain in the context of spasticity and is in routine use at Oxford since January 2024, but direct comparative data versus botulinum toxin remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the trial OR a positive opinion from a consultee is provided by a family member or carer (relative or friend) willing to provide personal consultee (PC) advice.
* Male or Female, aged 18 years or above.
* Diagnosed with a central neurological condition, including acquired brain injury (e.g. from ischaemic stroke, trauma, or haemorrhage), multiple sclerosis, and spinal cord injury.
* Clinical indication for Botulinum Toxin and Cryoneurolysis treatment, including pain associated with spasticity and with a clinically meaningful response to diagnostic nerve block to specific nerves or nerve branches that can be treated with cryoneurolysis.
* At least one rehabilitation goal related to management of pain resulting from spasticity.

Exclusion Criteria:

* Participant has received Botulinum toxin or cryoneurolysis within the last 90 days.
* Raynaud's syndrome.
* Cryoglobulinaemia.
* Cold urticaria.
* Bleeding disorders.
* Localised infection at intended treatment site.
* Planned oral antispasmodic medication dose changes.
* Pregnancy, breastfeeding, or planning pregnancy in the trial period.
* Scheduled elective surgery or other procedures requiring general anaesthesia during the trial.
* Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
* Participants who are currently enrolled in another trial may be excluded if it is deemed (in the investigator's opinion) that participation could influence the results for either study.

Where it's running

  • Oxford Centre for Enablement (OUH NHS-FT)
    Oxford, United Kingdom
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.